Develop therapeutic candidates for cardiovascular diseases. Develop therapeutic candidates for metabolic diseases. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 12.9× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 45% of them.
Analysts' average target sits 27% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Clearly below the class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Clearly above the class average — a step short of the very top.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades below its recent peak — about 11% off the top. A pullback, not a collapse.
The company sells $958.4M a year; the problem isn’t sales — it’s costs running above that number.
There is $983.6M in the vault; even if every debt were paid off, $629.2M would remain.
A loss of $288.3M against $958.4M in annual sales.
Over the last 12 months, executives reported 194 sells against just 41 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, MDGL sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: MDGL has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (45/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.